These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 31706700)

  • 1. Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
    Chayakulkeeree M; Tangkoskul T; Waywa D; Tiengrim S; Pati N; Thamlikitkul V
    J Mycol Med; 2020 Apr; 30(1):100905. PubMed ID: 31706700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus.
    Lai YW; Campbell LT; Wilkins MR; Pang CN; Chen S; Carter DA
    Int J Antimicrob Agents; 2016 Oct; 48(4):388-94. PubMed ID: 27474467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction.
    Rossato L; Loreto ÉS; Venturini TP; Azevedo MI; Weiblen C; Botton SA; Santurio JM; Alves SH
    Med Mycol; 2015 Nov; 53(8):885-9. PubMed ID: 26333356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of pyrvinium pamoate and posaconazole against
    Li Y; Li S; Chen M; Xiao J; Fang H
    Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
    Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human fungal pathogen Cryptococcus neoformans expresses three distinct iron permease homologs.
    Han K; Do E; Jung WH
    J Microbiol Biotechnol; 2012 Dec; 22(12):1644-52. PubMed ID: 23221526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron source preference and regulation of iron uptake in Cryptococcus neoformans.
    Jung WH; Sham A; Lian T; Singh A; Kosman DJ; Kronstad JW
    PLoS Pathog; 2008 Feb; 4(2):e45. PubMed ID: 18282105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
    Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
    Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.
    Alkashef NM; Seleem MN
    PLoS One; 2024; 19(8):e0308216. PubMed ID: 39088434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential of propolis on major virulence factors of Cryptococcus neoformans.
    Thammasit P; Iadnut A; Mamoon K; Khacha-Ananda S; Chupradit K; Tayapiwatana C; Kasinrerk W; Tragoolpua Y; Tragoolpua K
    Microb Pathog; 2018 Oct; 123():296-303. PubMed ID: 30041002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans.
    Pereira TC; de Menezes RT; de Oliveira HC; de Oliveira LD; Scorzoni L
    Pathog Dis; 2021 Feb; 79(2):. PubMed ID: 33417701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brilacidin, a novel antifungal agent against
    Diehl C; Pinzan CF; de Castro PA; Delbaje E; García Carnero LC; Sánchez-León E; Bhalla K; Kronstad JW; Kim D-g; Doering TL; Alkhazraji S; Mishra NN; Ibrahim AS; Yoshimura M; Vega Isuhuaylas LA; Pham LTK; Yashiroda Y; Boone C; Dos Reis TF; Goldman GH
    mBio; 2024 Jul; 15(7):e0103124. PubMed ID: 38916308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts.
    Spadari CC; Vila T; Rozental S; Ishida K
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844051
    [No Abstract]   [Full Text] [Related]  

  • 18. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between antifungals and everolimus against
    Liang P; Song J; Liu Q
    Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
    Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.